OrbiMed Buys $20M of Windward Bio IPO Shares at $17.00
WWB sits 22% above its 52-week low of $18.35.
Summary
OrbiMed bought 1,176,471 Windward Bio shares at $17.00 for $20.0 million in the IPO, alongside a 5.17 million-share preferred conversion and a small warrant exercise, ending with 7.10 million shares.
Key Events · Ownership and Investor Activity · WWB
-
OrbiMed Buys $20M at IPO Price
OrbiMed Private Investments IX bought 1,176,471 common shares at $17.00 on 2026-11-16 for $20,000,007 in the IPO.
-
Preferred Converts 1:1 Into Common
3,561,936 Series A and 1,611,008 Series B preferred shares converted into common on a 1-to-1 basis immediately prior to the IPO closing.
-
Warrants Exercised, Shares Withheld
216,668 warrants were exercised at $0.02, and 232 shares were withheld at $17.00 for taxes, a $3,944 disposition.
-
Post-Deal Stake 7.10M Shares
Following the purchase, conversion and exercise, OrbiMed indirectly holds 7,097,483 common shares.
Analysis · WWB · Life Sciences
OrbiMed, a director and 10% owner, put $20 million of real money into Windward Bio's IPO at the $17.00 offer price — an open-market purchase, not an option exercise or grant. The same filing shows 5.17 million preferred shares converting 1:1 into common and 216,668 warrants exercised at $0.02, leaving OrbiMed with 7.10 million shares. The purchase is a strong vote of confidence from a specialist healthcare investor at the exact IPO price, though the conversion and warrant exercise add to the tradable share base rather than representing new cash.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, WWB was trading at $22.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $18.35 to $33.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.